Abstract library

401 results for "serum levels of CgA".
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#1145 The Association Between Gastrin and Glucose Serum Concentration
Introduction: Gastrin is an early incretin candidate, since it is released by oral glucose and potentiates the glucose- induced insulin secretion. It has been shown that only in hypoglycemic or hyperglycemic conditions gastrin release is influenced by changes in blood glucose and insulin concentrations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD Krystallenia Alexandraki
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#2256 Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms
Introduction: Tumor growth and the ability to metastasize is a multistage process involving interactions between cancer cells and the vascular endothelium. These interactions have been reported to be mediated by various molecules including sVCAM-1. We have previously shown elevated serum concentration of sVCAM-1 in 82 neuroendocrine neoplasms (NEN) compared to controls. Here, we present results of the extension of the previous study.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: MD PhD Violetta Rosiek
#623 Measurement of Serum Chromogranin A Level in 56 Patients with Neuroendocrine Tumors Using Immunoradiometric Assay
Introduction: More NETs have been diagnosed with the increasing awareness of the diseases, but few centers in China have introduced CgA testing as a tumor marker.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: professor Huangying Tan
Authors: Tan H, Jia L, ...
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico
#1658 The Clinical Significance of Elevated Serum Procalcitonin in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Elevated serum procalcitonin (PCT) was reported in some patients with neuroendocrine neoplasms (NEN), but its clinical significance in gastroenteropancreatic NEN (GEP-NEN) was still unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Jie Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?
Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Thomas Walter
Keywords: thyrocalcitonin
#1325 Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Franco Grimaldi
Authors: Grimaldi F, Motta C, Cipri C, Tonelli V, ...
Keywords: Tumor marker
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran